Abstract
Sixty-nine unselected patients with locally advanced and metastatic carcinoma of the pancreas, who had not received previous chemotherapy or radiotherapy were randomised to receive either 5-fluorouracil, epirubicin and mitomycin C (FEM) or epirubicin. Survival was not significantly different in the two arms. Toxic reactions (WHO grade greater than 3) in the FEM and epirubicin arm respectively included nausea (2), (4), severe alopecia (1) (3) and leucopenia (1), (5), none of these were statistically significant. We therefore suggest that combination chemotherapy should not be used in preference to single agent chemotherapy as standard treatment for locally advanced or metastatic cancer of the pancreas.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Cullinan S. A., Moertel C. G., Fleming T. R., Rubin J. R., Krook J. E., Everson L. K., Windschitl H. E., Twito D. I., Marschke R. F., Foley J. F. A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin. JAMA. 1985 Apr 12;253(14):2061–2067. [PubMed] [Google Scholar]
- Komaki R., Hansen R., Cox J. D., Wilson J. F. Phase I-II study of prophylactic hepatic irradiation with local irradiation and systemic chemotherapy for adenocarcinoma of the pancreas. Int J Radiat Oncol Biol Phys. 1988 Dec;15(6):1447–1452. doi: 10.1016/0360-3016(88)90242-8. [DOI] [PubMed] [Google Scholar]
- O'Connell M. J. Current status of chemotherapy for advanced pancreatic and gastric cancer. J Clin Oncol. 1985 Jul;3(7):1032–1039. doi: 10.1200/JCO.1985.3.7.1032. [DOI] [PubMed] [Google Scholar]
- Wils J., Bleiberg H., Blijham G., Dalesio O., Duez N., Lacave A., Splinter T. Phase II study of epirubicin in advanced adenocarcinoma of the pancreas. Eur J Cancer Clin Oncol. 1985 Feb;21(2):191–194. doi: 10.1016/0277-5379(85)90172-5. [DOI] [PubMed] [Google Scholar]